Drug intelligence / Profile preview

IL-32 inhibitor (Arch Biopartners)

Development stage: Preclinical
Lead developer: 1502440

Overview

Arch Biopartners is developing a therapeutic platform targeting interleukin-32 (IL-32) for the treatment of diabetic kidney disease (DKD) and chronic kidney disease (CKD). IL-32 is a non-classical cytokine involved in regulating inflammation and immune responses, which has been implicated in the pathogenesis of diabetic CKD. The program is a result of a collaboration between the National Research Council of Canada (NRC), Lipdro, and Arch Biopartners. Currently in the preclinical stage, the company is working toward selecting a lead candidate and filing an Investigational New Drug (IND) application with the FDA.

Other names: CKD PlatformIL-32 programIL32 programIL 32 program

Targets

IL32 (IL-32)

Beyond the preview

Go deeper on IL-32 inhibitor (Arch Biopartners).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IL-32 inhibitor (Arch Biopartners).

Explore the full profile